Hangzhou New Horizon Health Technology Co., Ltd.

The company manufactures diagnostic devices for HPV detection, including a high-risk HPV DNA test using PCR-fluorescence probing technology, as well as nucleic acid extraction and purification reagents and kits for laboratory use. It also produces sample collection and preservation tubes for cervical, vaginal, and urine specimens, alongside software for combined genetic mutation and methylation analysis in colorectal cancer screening. Additional offerings include a device for fecal immunochemical testing (FIT) and a reusable UU tube for medical procedures.

The portfolio includes in vitro diagnostic (IVD) devices classified under Class A and IVD General, with some products registered in the EU’s eudamed database. The company is based in China and adheres to relevant regulatory frameworks for diagnostic medical devices in its market and export jurisdictions.

AI-generated from registry data, 19 Sep 2026. Not verified by deviCERTS or the manufacturer.

THE FIRST HIGH-TECH COMPANY IN CHINA, WHICH FOCUSES ON EARLY CANCER SCREENING, HAS PIONEERED THE CONCEPT OF SERVICES FOR “EARLY HOME SCREENING FOR HIGH-PREVALENCE CANCER”. ITS OWN “NON-INTRUSIVE, MULTI-TARGET FIT-DNA JOINT TEST” PRODUCT - THE FIRST EVER IN CHINA AND THE ONLY EARLY SCREENING PRODUCT FOR ENTERIC CANCER AT THIS STAGE. THE PRODUCT LINE COVERS AREAS SUCH AS ENTERIC, CERVICAL, STOMACH AND LUNG CANCER. WITH REGARD TO THE HIGH INCIDENCE OF CANCER AMONG CHINESE PEOPLE, NOBUMI HEALTH IS COMMITTED TO PROVIDING THE MOST APPROPRIATE EARLY SCREENING SOLUTIONS, SO THAT USERS CAN HAVE ACCESS TO EARLY CANCER SCREENING SERVICES THAT ARE ACCURATE, EFFICIENT AND ACCESSIBLE。

Translated from the manufacturer's own website. Source

Generated automatically from registry data and not verified by a human reviewer.